(19)
(11) EP 2 041 180 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
05.03.2014 Bulletin 2014/10

(45) Mention of the grant of the patent:
29.01.2014 Bulletin 2014/05

(21) Application number: 07872531.4

(22) Date of filing: 19.06.2007
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C07K 16/28(2006.01)
(86) International application number:
PCT/US2007/014239
(87) International publication number:
WO 2008/094176 (07.08.2008 Gazette 2008/32)

(54)

ILT3 BINDING MOLECULES AND USES THEREFOR

ILT3-BINDENDE MOLEKÜLE UND VERWENDUNGEN DAVON

MOLÉCULES SE LIANT À L'ILT3 ET LEURS UTILISATIONS


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 19.06.2006 US 814931 P

(43) Date of publication of application:
01.04.2009 Bulletin 2009/14

(73) Proprietor: Liquidating Trust
N. Bethesda, MD 20852 (US)

(72) Inventors:
  • PONATH, Paul
    San Francisco, CA 94114 (US)
  • ROSENZWEIG, Michael
    Boston, MA 02116 (US)
  • PONTE, Jose, F.
    South Boston, MA 02127 (US)

(74) Representative: Nash, David Allan 
Haseltine Lake LLP Redcliff Quay 120 Redcliff Street
Bristol BS1 6HU
Bristol BS1 6HU (GB)


(56) References cited: : 
WO-A1-01/83560
WO-A1-94/13805
WO-A1-98/40488
WO-A2-03/048321
WO-A2-03/075855
WO-A2-2006/025060
US-A1- 2002 132 983
US-A1- 2005 214 205
WO-A1-94/12661
WO-A1-96/06863
WO-A2-98/33919
WO-A2-03/075846
WO-A2-2003/038043
WO-A2-2006/138739
US-A1- 2004 241 167
US-B1- 6 821 724
   
  • CHANG C C ET AL: "Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4" NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 3, no. 3, 1 March 2002 (2002-03-01), pages 237-243, XP002558309 ISSN: 1529-2908 [retrieved on 2002-01-28]
  • CELLA M ET AL: "A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing" 19970519, vol. 185, no. 10, 19 May 1997 (1997-05-19) , pages 1743-1751, XP002477138
  • KHEE HWANG W Y ET AL: "Use of human germline genes in a CDR homology-based approach to antibody humanization" METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 35-42, XP004852551 ISSN: 1046-2023
  • WALLET ET AL.: 'Immunoregutation of Dendritic Cells.' CLINICAL MEDICINE & RESEARCH vol. 3, no. 3, pages 166 - 175, XP008107843
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).